Cancer Medicine · us
Delivering Immune Signals Deep Into Tumors: Engineered Bifidobacteria Enhance Treatment in Mice With Pancreatic Cancer
Researchers engineered Bifidobacterium longum to preferentially colonize hypoxic tumors and locally release a modified version of IL-2. Mouse experiments showed that it can activate cancer-killing T cells and enhance chemotherapy, radiotherapy, and immunotherapy, but multiple safety hurdles remain before human use.
Pancreatic cancer is not only difficult to detect early; it is also adept at keeping immune attacks at bay. Its dense, hypoxic microenvironment often lacks active immune cells, making it difficult for various immunotherapies that work in other cancers to be effective. A University of Chicago research team is now attempting to turn this hypoxic region to its advantage by sending genetically engineered bacteria into tumors to produce immune-stimulating molecules there.
This experimental therapy, called BifidoSumIL-2, uses Bifidobacterium longum, a bacterium commonly found in the gut, as its delivery vehicle. Researchers engineered it to release SumIL-2, a modified interleukin-2 variant designed to preferentially activate T cells that carry out anticancer functions while reducing stimulation of regulatory T cells that may suppress immune responses. The study was published on July 23, 2026, in the peer-reviewed journal *Science Advances*.
Bifidobacteria are anaerobic bacteria, and oxygen-rich normal tissues are unfavorable for their growth, while low-oxygen regions within pancreatic tumors may provide a place for them to establish themselves. After systemic injection, the bacteria in the study accumulated preferentially in tumors, effectively setting up miniature drug factories within the lesions. The concept is intended to address the dilemma that conventional IL-2 can cause toxicity after entering systemic circulation yet may still fail to reach a sufficiently effective concentration within tumors.
In subcutaneous and orthotopic mouse models of pancreatic ductal adenocarcinoma, BifidoSumIL-2 increased the activity of CD8-positive T cells within tumors and inhibited tumor growth. When combined separately with chemotherapy, radiotherapy, or anti-PD-L1 checkpoint inhibitor therapy, tumor control and animal survival were better than with each treatment used alone, suggesting that local immune stimulation may help tumors that were previously poorly responsive become susceptible to attack again.
However, the term “probiotic” does not mean that this therapy is equivalent to an edible or naturally safe product. The study used live bacteria that were genetically engineered and administered by systemic injection; all current evidence comes from animal models, and the therapy has not yet entered human trials. Tumor colonization and therapeutic effects in mice also cannot be directly assumed to recur in human pancreatic cancer.
The next key questions include long-term safety, whether the bacteria could remain in unintended tissues, how long the immune response can be sustained, and how the engineered bacteria could be controlled or eliminated after treatment ends. The research team also proposed the possibility of exploring oral delivery and combinations with KRAS inhibitors in the future, but these approaches remain to be validated. For now, the most important significance of these findings is that they demonstrate that live bacteria may be able to serve simultaneously as tumor-targeting guides and local drug-production platforms—not that a usable new therapy is now available to patients with pancreatic cancer.